We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Walking the plank

25 May 2004 By Robert Cyran

With investors fleeing risk, a biotech float is the last thing one would expect. Yet companies are lining up. The reason? They have little choice as their cash piles burn away.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)